---
schema_version: "secwatch.filing_event.v1"
accession: "0001683168-25-006727"
form_type: "8-K"
ticker: "PMCB"
cik: "0001157075"
company_name: "PharmaCyte Biotech, Inc."
filed_at: "2025-09-05T23:59:59+00:00"
generated_at: "2026-05-17T07:52:46.956739+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.55
calibrated_materiality_score: 0.55
confidence: "high"
source: SEC EDGAR
---

# PharmaCyte Biotech invests $3M in TNF Pharma for convertible preferred and warrants linked to LightSolver license

## Summary
- PharmaCyte purchased $3M of TNF Series H convertible preferred shares (convertible at $5) and warrants for 600,000 common shares at $5 exercise price.
- Investment supports TNF's license with LightSolver for a light-speed computing platform for cryptocurrency mining and blockchain.
- TNF plans to change its name and ticker to reflect the new strategy; warrants expire 5 years after stockholder approval.
- Preferred shares carry 7% annual dividend (15% on trigger events) and price-based anti-dilution adjustments.
- PharmaCyte reports total assets over $55M as of April 30, 2025, and will use cash for this investment.

## SEC filing metadata
- accession: 0001683168-25-006727
- form_type: 8-K
- ticker: PMCB
- cik: 0001157075
- company_name: PharmaCyte Biotech, Inc.
- filed_at: 2025-09-05T23:59:59+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.55
- calibrated_materiality_score: 0.55
- confidence: high
- sec_items: 1.01, 2.01, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1157075/000168316825006727/0001683168-25-006727-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1157075/000168316825006727/pharmacyte_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001683168-25-006727
- JSON: https://secwatch.observer/filing/0001683168-25-006727.json
- Plain text: https://secwatch.observer/filing/0001683168-25-006727.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.